Latest Insider Transactions at Bei Gene, Ltd. (BGNE)
This section provides a real-time view of insider transactions for Bei Gene, Ltd. (BGNE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BeiGene, Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BeiGene, Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2020
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Dec 18
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
25,762
+0.14%
|
$6,698,120
$260.95 P/Share
|
|
Dec 17
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
74,624
+0.4%
|
$19,402,240
$260.54 P/Share
|
|
Dec 16
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
85,573
+0.46%
|
$21,222,104
$248.26 P/Share
|
|
Dec 15
2020
|
Xiaodong Wang Director |
SELL
Bona fide gift
|
Direct |
165,295
-2.82%
|
-
|
|
Dec 15
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
67,941
+0.36%
|
$16,237,899
$239.31 P/Share
|
|
Dec 14
2020
|
Howard Liang CFO & Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
91,900
-32.44%
|
$20,953,200
$228.58 P/Share
|
|
Dec 14
2020
|
Howard Liang CFO & Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
91,900
+50.0%
|
$551,400
$6.5 P/Share
|
|
Dec 14
2020
|
Howard Liang CFO & Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,405,300
+47.17%
|
$0
$0.5 P/Share
|
|
Dec 11
2020
|
John Oyler Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
545,597
+50.0%
|
-
|
|
Dec 11
2020
|
John Oyler Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
2,136,914
-12.63%
|
-
|
|
Dec 10
2020
|
Xiaodong Wang Director |
BUY
Bona fide gift
|
Indirect |
1,244,542
+50.0%
|
-
|
|
Dec 10
2020
|
Xiaodong Wang Director |
SELL
Bona fide gift
|
Direct |
1,332,552
-9.36%
|
-
|
|
Dec 04
2020
|
Donald W. Glazer Director |
SELL
Bona fide gift
|
Direct |
589,849
-16.86%
|
-
|
|
Dec 04
2020
|
Baker Bros. Advisors LP |
SELL
Open market or private sale
|
Indirect |
1,511,546
-11.36%
|
$332,540,120
$220.5 P/Share
|
|
Nov 30
2020
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-29.69%
|
$402,000
$268.94 P/Share
|
|
Nov 30
2020
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Oct 29
2020
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-80.74%
|
$450,000
$300.7 P/Share
|
|
Oct 29
2020
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Oct 16
2020
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Indirect |
5,000
-100.0%
|
$1,600,000
$320.0 P/Share
|
|
Oct 13
2020
|
Baker Bros. Advisors LP |
SELL
Bona fide gift
|
Direct |
27,032
-56.47%
|
-
|
|
Oct 05
2020
|
Howard Liang CFO & Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
14,000
-30.64%
|
$4,172,000
$298.89 P/Share
|
|
Oct 05
2020
|
Howard Liang CFO & Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+50.0%
|
$84,000
$6.5 P/Share
|
|
Oct 05
2020
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
4,000
-100.0%
|
$1,200,000
$300.0 P/Share
|
|
Oct 05
2020
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Indirect |
5,000
-100.0%
|
$1,500,000
$300.0 P/Share
|
|
Sep 29
2020
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-62.9%
|
$420,000
$280.16 P/Share
|
|
Sep 29
2020
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Sep 29
2020
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
23,303
-34.04%
|
$6,478,234
$278.75 P/Share
|
|
Sep 28
2020
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
31,000
-57.33%
|
$8,680,000
$280.38 P/Share
|
|
Aug 25
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
59,390
+0.32%
|
$14,728,720
$248.49 P/Share
|
|
Aug 24
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
59,390
+0.32%
|
$14,194,210
$239.1 P/Share
|
|
Aug 21
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
64,176
+0.35%
|
$14,760,480
$230.18 P/Share
|
|
Aug 20
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
64,176
+0.35%
|
$15,017,184
$234.99 P/Share
|
|
Aug 19
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
64,176
+0.35%
|
$15,017,184
$234.88 P/Share
|
|
Aug 18
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+0.22%
|
$9,200,000
$230.18 P/Share
|
|
Jul 15
2020
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
14,584,180
+45.61%
|
$204,178,520
$14.23 P/Share
|
|
Jul 15
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
29,614,832
+11.14%
|
$414,607,648
$14.23 P/Share
|
|
Jun 06
2019
|
Baker Bros. Advisors LP |
BUY
Other acquisition or disposition
|
Direct |
86,218
+50.0%
|
-
|
|
Jun 06
2019
|
Baker Bros. Advisors LP |
SELL
Other acquisition or disposition
|
Indirect |
582,200
-96.91%
|
-
|
|
Jun 06
2019
|
Baker Bros. Advisors LP |
BUY
Other acquisition or disposition
|
Direct |
27,032
+39.6%
|
-
|
|
Jun 06
2019
|
Baker Bros. Advisors LP |
SELL
Other acquisition or disposition
|
Indirect |
182,539
-15.08%
|
-
|
|
Aug 02
2018
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
5,814,100
+49.56%
|
$627,922,800
$108.0 P/Share
|
|
Jun 06
2018
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
37,160
+0.15%
|
-
|
|
Jan 18
2018
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
1,980,198
+28.22%
|
$199,999,998
$101.0 P/Share
|
|
Oct 13
2017
|
Baker Bros. Advisors LP |
BUY
Other acquisition or disposition
|
Direct |
14,204
+50.0%
|
-
|
|
Oct 13
2017
|
Baker Bros. Advisors LP |
SELL
Other acquisition or disposition
|
Indirect |
49,200
-100.0%
|
-
|
|
Feb 08
2016
|
Merck & Co., Inc. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
7,942,314
+50.0%
|
-
|
|
Feb 08
2016
|
Merck & Co., Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
23,646,724
+50.0%
|
-
|